Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes: full-pipeline trial registry
103 of 289 indexed Type 2 Diabetes trials are currently recruiting.
Corpus placement: #30 of 28,963 conditions by registered trial count.
289 US clinical trials · 103 currently recruiting · #30 of 28,963 conditions by registered trial count
Type 2 Diabetes: 289 US clinical trials tracked, 103 recruiting.
Type 2 Diabetes is the subject of 289 registered US clinical trials on ClinicalTrials.gov, 103 of them currently open to new participants. 56 are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 20 of these trials.
Open enrollment snapshot
Type 2 Diabetes has 289 registered US clinical trials, 103 of them open to new participants right now, about 36% of the total.
- 103
- recruiting participants now
- 36%
- of trials open to enrollment
- 56
- in Phase 3-4 (later-stage)
- 20
- top sponsor: Eli Lilly and Company
Corpus placement: #30 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes recruits in line with its size-band peers.
103 of 289 indexed trials (35.6%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes trials is spread across many organizations.
Eli Lilly and Company accounts for 20 of 289 trials (6.9%). 140 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes enrolment sits around 96 participants.
Median target enrolment is 96 among the 289 trials that report a genuine target (sentinel values excluded). 145 of those (50.2%) plan for fewer than 100 participants.
-
Type 2 Diabetes research is mostly interventional.
257 interventional and 32 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
289 total, page 4 of 6
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
University of Minnesota
NCT06465693
Extension for Community Health Outcomes (ECHO) Diabetes Program
University of Florida
NCT06552923
Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment
AstraZeneca
NCT02917057
Gene x Behavior Interaction in the Look AHEAD Study
The Miriam Hospital
NCT01270763
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
VIVUS
NCT00553787
Vitamin D and Type 2 Diabetes Study
Tufts Medical Center
NCT01942694
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Eli Lilly and Company
NCT03987919
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT05872620
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
AstraZeneca
NCT00673231
Improving Self Management Skills of Older Adults With Diabetes
Stanford University
NCT01943357
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
AstraZeneca
NCT00643851
Bronx A1c: Bring it Down for Health
Albert Einstein College of Medicine
NCT00797888
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Eli Lilly and Company
NCT05362058
Dapagliflozin DPPIV Inhibitor add-on Study
AstraZeneca
NCT00984867
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Eli Lilly and Company
NCT05662332
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Sanofi
NCT02058160
A 2-Month Safety Follow-Up Trial
Mannkind Corporation
NCT00741429
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Eli Lilly and Company
NCT01624259
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Sanofi
NCT00299871
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Intarcia Therapeutics
NCT01455870
Fresh Food Farmacy: A Randomized Controlled Trial
John B Bulger, DO
NCT03718832
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
AstraZeneca
NCT02284893
Latinos Understanding the Need for Adherence in Diabetes
San Diego State University
NCT03983499
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
AstraZeneca
NCT00757588
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Amgen
NCT02739984
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
Gilead Sciences
NCT00353587
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Metabolic Solutions Development Company
NCT01103414
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Mannkind Corporation
NCT01451398
Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications
University of Colorado, Denver
NCT05166382
Family Model Diabetes Self-Management Education in Faith Based Organizations
University of Arkansas
NCT04256486
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Eli Lilly and Company
NCT02973100
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
AstraZeneca
NCT01619059
Power-Up: An Effectiveness Trial of the Diabetes Prevention Program
Albert Einstein College of Medicine
NCT04104243
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
Daiichi Sankyo
NCT00147719
Changing Health Through Food Support for Diabetes
University of California, San Francisco
NCT04959487
Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)
Joslin Diabetes Center
NCT00392678
Diabetes Support Project: Couples Intervention
State University of New York - Upstate Medical University
NCT01017523
REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes
University of Pittsburgh
NCT01611168
Taking Action Together- A Diabetes Prevention Program
University of California, Berkeley
NCT01039116
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
AstraZeneca
NCT02288273
UCSD Take Charge Study
University of California, San Diego
NCT01345500
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
Biogen
NCT00811889
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
AstraZeneca
NCT00918138
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone
ActivX Biosciences
NCT00525330
Physical Health in Midlife: Influences of Adversity and Relationships Over Time
Beth Israel Deaconess Medical Center
NCT01853332
Medically Tailored Groceries and Food Resource Coaching
University of Texas Southwestern Medical Center
NCT06242808
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Hanmi Pharmaceutical Company Limited
NCT02081118
Video Games for Obesity and Diabetes Prevention-Diab & Nano
Baylor College of Medicine
NCT01846377
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
Eli Lilly and Company
NCT04605991
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
Jiangsu HengRui Medicine Co.
NCT04663282
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 21 |
| Phase 3 | 34 |
| Phase 4 | 22 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Type 2 Diabetes right now
103 recruiting of 289 indexed (36% open).
Phase mix: 56 late (III/IV) vs 42 early (I/II) (balanced across stages).
Top sponsor: Eli Lilly and Company (20 trials), 9 others listed. 50 shown below, recruiting first. #30 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Type 2 Diabetes?
PlainTrial tracks 289 US clinical trials for Type 2 Diabetes, of which 103 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Type 2 Diabetes?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.